Akorn, FDC seek approval for generic ophthalmic solution

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Akorn, Inc. submitted its first abbreviated New Drug Application with the Office of Generic Drugs for an ophthalmic solution on behalf of FDC Ltd., as part of the companies' purchase and supply agreement.

"We are pleased to announce this new product submission on behalf of FDC. FDC will develop, manufacture and supply finished dosage form drug products to Akorn and we are responsible for filing FDA regulatory submissions on behalf of FDC. Akorn has exclusive U.S. marketing rights to all drug products filed on behalf of FDC," Akorn president and chief executive officer Arthur S. Przybyl said in a news release.

Akorn is a pharmaceutical company based in Buffalo Grove, Ill.

FDC is a Maharashtra, India-based manufacturer of ophthalmic pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.